Indiana 2026 Regular Session Status: Passed Senate Bipartisan · 4 R · 2 D cosponsors

SB 157 — Disclosures related to prescription drugs.

Last action — First reading: referred to Committee on Public Health

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill has passed the Senate. Introduced January 05, 2026. It now moves to the second chamber.

Next likely step: consideration and a floor vote in the House.

Odds of enactment

Moderate chance

Based on the sponsor, cosponsors, and committee posture, this bill has a moderate chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 54% · moderate confidence

  • Passed Senate

    Current position in the legislative process.

  • 6 sponsors

    3 primary, 3 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (4 R · 2 D) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

Requires certain pharmacists or pharmacies to provide the amount of the national average drug acquisition cost for a generic drug on the written materials provided to an individual at the point of sale of the generic drug.

Bill Text

Action History

  1. First reading: referred to Committee on Public Health

  2. Referred to the House

  3. Cosponsor: Representative Barrett

  4. House sponsor: Representative Goss-Reaves

  5. Senator Crider added as second author

  6. Third reading: passed; Roll Call 72: yeas 44, nays 0

  7. Amendment #1 (Bohacek) prevailed; voice vote

  8. Second reading: amended, ordered engrossed

  9. Committee report: amend do pass, adopted

  10. Senator Randolph added as coauthor

  11. Senator Jackson L added as coauthor

  12. Authored by Senator Bohacek

  13. First reading: referred to Committee on Insurance and Financial Institutions

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

3 sponsors · 3 co-sponsors · 144 not signed on

Sponsors (3)

Co-sponsors (3)

Not signed on (144)

144 members have not signed on to this bill.

Show all 144 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 157 do?
Requires certain pharmacists or pharmacies to provide the amount of the national average drug acquisition cost for a generic drug on the written materials provided to an individual at the point of sale of the generic drug.
Who sponsors SB 157?
SB 157 is sponsored by Brad Barrett (Republican), Lori Goss-Reaves (Republican), Lonnie Randolph (Democrat), La Keisha Jackson (Democrat), Michael Crider (Republican), and Mike Bohacek (Republican).
What is the current status of SB 157?
This bill has passed the Senate. Introduced January 05, 2026. It now moves to the second chamber.
Where can I track SB 157?
Track SB 157 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 157

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 157

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →